CrawfordE.B., EisènbergerM.A., Mc LeodB., SpauldingJ.T., BensonR., DorrF.A., BlumensteineB.A., DavisM.A., GoodmanP.J.: A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N. Engl. J. Med., 321; 419–424 (1989).
2.
Di SilverioF., SerioM., TenagliaR., SelliC., D'EramoG.: Zoladex Depot vs blocco androgenico totale nella terapia del carcinoma prostatico avanzato. Acta Urol. Ital., 2; Suppl. I, 79–87 (1988).
3.
Hug-ginsC., HodgesC.V.: Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on the normal and on the hyperplastic prostate gland of dogs. Cancer Res., 1; 293 (1941).
4.
HugginsC., StevensR.E.Jr., HodgesC.V.: Studies on prostatic cancer. II. Effects of castration on advanced carcinoma of the prostate gland. Arch. Surg., 43; 209 (1941).
5.
LabrieF., DupontA., BelangerA., CusanL., LacourciereY., MonfetteG., LabergeJ.G., EmondJ.P., FazekasA.T.A., RaynaudJ.P., HussonJ.M.: New ormonal therapy in prostatic carcinoma: combined treatment with an LH-RH agonist and an antiandrogen. Clin. Invest. Med., 5; 267–275 (1982).
6.
LabrieF., DupontA., BelangerA., LacourcièreY., RaynaudJ.P., HussonJ.M., FazekasA.T.A., SandowJ., MonfetteG., GirardJ.G., EmondJ., HouleJ.G.: New approach in the treatment of prostate cancer. Complete instead of only partial withdrawal of androgens. Prostate, 4; 579–594 (1983).
7.
LabrieF., DupontA., BelangerA., LefebvreF.A., CusanL., RaynaudJ.P., HussonJ.M., FazekasA.T.A.: New hormonal therapy in prostate cancer. Combined use of a pure androgen and an LH-RH agonist. Horm. Res., 18; 18–27 (1983).
8.
LabrieF., DupontA., BelangerA.: Genitourinary Cancer.RattittT.E., CatalonaW.S. (eds). Martinus Nijoff Publ., Boston (1987).
9.
MurphyG.B., SlackN.H.: Response criteria of the USA National Prostatic Cancer Project. Prostate, 1; 375–382 (1980).